Case Report: Frontline CD19 CAR-T-cell therapy combined with targeted regimens induces durable complete remission in newly diagnosed secondary CNS lymphoma: a report of two cases. (PubMed, Front Oncol) - Oct 2, 2026 - "Standard-of-care treatments based on high-dose methotrexate often yield suboptimal outcomes...Case 1 (65-year-old male) received Pola-ZR induction therapy (polatuzumab vedotin, zanubrutinib, and rituximab), while Case 2 (56-year-old female) received ZPR induction therapy (zanubrutinib, pomalidomide, and rituximab) followed by autologous stem cell transplantation...Rapid CR was achieved and maintained for 24 and 21 months, respectively, with manageable toxicities. Frontline CAR-T-cell therapy combined with targeted agents may constitute a promising therapeutic paradigm for newly diagnosed SCNSL, yet these hypothesis-generating findings require validation in larger patient cohorts."
Journal • CNS Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Secondary Central Nervous System Lymphoma • Transplantation
|
|
Fenghua Gao; Hao Guo; Jingyi Yang; Keshu Zhou; Qianying Pan; Qing Zhang; Ran Zhao; Xingchen Liu; Xueli Jiao
|